Analysts think RYTM stock price could increase by 41%
May 11, 2025, 11:25 AM
16.47%
What does RYTM do
Rhythm Pharmaceuticals, based in Boston, develops therapeutics for rare diseases, focusing on melanocortin-4 receptor agonists like IMCIVREE, approved for chronic weight management in specific obesity cases. The company employs 226 people and went public in October 2017.
14 analysts think RYTM stock price will increase by 40.55%. The current median analyst target is $80.58 compared to a current stock price of $57.33. The lowest analysts target is $65.65 and the highest analyst target is $98.70.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
